Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Elbasvir

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Elbasvir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antivirals for treatment of hcv infections
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP10

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis69.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Elbasvir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Elbasvir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Impact of Hepatitis C Therapy and Bone Health

    NCT03221582 · start 2017-08-28

    Registered record
    Registry ID
    NCT03221582
    Conditions
    Human Immunodeficiency Virus; Hepatitis C
    Interventions
    EBR/GZR
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-08-28
    Completion
    2018-11-30
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus; Hepatitis C
    InterventionEBR/GZR
    PhasePhase 4
    Registry statusTerminated

  • A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A

    NCT03105349 · start 2017-07-01

    Registered record
    Registry ID
    NCT03105349
    Conditions
    HCV
    Interventions
    elbasvir/grazoprevir; Sofosbuvir; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2017-07-01
    Completion
    2018-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHCV
    Interventionelbasvir/grazoprevir; Sofosbuvir; Ribavirin
    PhasePhase 4
    Registry statusWithdrawn

  • 8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis

    NCT03186365 · start 2017-06-12

    Registered record
    Registry ID
    NCT03186365
    Conditions
    Hepatitis C, Chronic
    Interventions
    Zepatier Oral Product
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-06-12
    Completion
    2018-09-19
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionZepatier Oral Product
    PhasePhase 3
    Registry statusCompleted

  • Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney Disease

    NCT03145623 · start 2017-06-02

    Registered record
    Registry ID
    NCT03145623
    Conditions
    Hepatitis C; Chronic Kidney Diseases
    Interventions
    Elbasvir and Grazoprevir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-06-02
    Completion
    2017-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Chronic Kidney Diseases
    InterventionElbasvir and Grazoprevir
    PhaseNot recorded
    Registry statusCompleted

  • Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4

    NCT02886624 · start 2017-05-31

    Registered record
    Registry ID
    NCT02886624
    Conditions
    Acute Hepatitis C; HIV
    Interventions
    Grazoprevir/Elbasvir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-05-31
    Completion
    2019-09-16
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Hepatitis C; HIV
    InterventionGrazoprevir/Elbasvir
    PhasePhase 2
    Registry statusCompleted

  • Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care

    NCT03093415 · start 2017-05-30

    Registered record
    Registry ID
    NCT03093415
    Conditions
    Hepatitis C; Substance Use Disorders; Substance Abuse, Intravenous
    Interventions
    elbasvir-grazoprevir (50 mg/100 mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-05-30
    Completion
    2019-06-06
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Substance Use Disorders; Substance Abuse, Intravenous
    Interventionelbasvir-grazoprevir (50 mg/100 mg)
    PhasePhase 4
    Registry statusCompleted

  • Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)

    NCT03146741 · start 2017-05-16

    Registered record
    Registry ID
    NCT03146741
    Conditions
    Heart Failure
    Interventions
    Zepatier
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2017-05-16
    Completion
    2019-11-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionZepatier
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant

    NCT02902120 · start 2017-05-01

    Registered record
    Registry ID
    NCT02902120
    Conditions
    Hepatitis C; Renal Insufficiency, Chronic; Disorder of Transplanted Kidney
    Interventions
    Post-transplant Grazoprevir and Elbasvir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-05-01
    Completion
    2022-06-08
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Renal Insufficiency, Chronic; Disorder of Transplanted Kidney
    InterventionPost-transplant Grazoprevir and Elbasvir
    PhasePhase 4
    Registry statusCompleted

  • the Effect of Grazoprevir/Elbasvir and TACE vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated HCC.

    NCT03110055 · start 2017-05-01

    Registered record
    Registry ID
    NCT03110055
    Conditions
    HCV, HCC
    Interventions
    Grazoprevir/Elbasvir; Medical records; Transarterial Chemoembolization
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-05-01
    Completion
    2019-05-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHCV, HCC
    InterventionGrazoprevir/Elbasvir; Medical records; Transarterial Chemoembolization
    PhaseNot applicable
    Registry statusUnknown

  • Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients

    NCT02897596 · start 2017-04-28

    Registered record
    Registry ID
    NCT02897596
    Conditions
    Hepatitis C; HIV
    Interventions
    Grazoprevir 100 mg/d 8 weeks; Elbasvir 50 mg/d 8 weeks; Grazoprevir 100 mg/d 12 weeks; Elbasvir 50 mg/d 12 weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2017-04-28
    Completion
    2019-10-30
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; HIV
    InterventionGrazoprevir 100 mg/d 8 weeks; Elbasvir 50 mg/d 8 weeks; Grazoprevir 100 mg/d 12 weeks; Elbasvir 50 mg/d 12 weeks
    PhasePhase 3
    Registry statusUnknown

  • A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir

    NCT03144635 · start 2017-04-01

    Registered record
    Registry ID
    NCT03144635
    Conditions
    Hepatitis C Viral; Chronic Kidney Disease stage3
    Interventions
    Grazoprevir plus Elbasvir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-04-01
    Completion
    2018-09-20
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Viral; Chronic Kidney Disease stage3
    InterventionGrazoprevir plus Elbasvir
    PhasePhase 4
    Registry statusCompleted

  • Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort

    NCT03111966 · start 2017-03-31

    Registered record
    Registry ID
    NCT03111966
    Conditions
    Hepatitis C
    Interventions
    Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-03-31
    Completion
    2017-11-30
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionSpanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir
    PhaseNot recorded
    Registry statusCompleted

  • Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant

    NCT02945150 · start 2017-02-01

    Registered record
    Registry ID
    NCT02945150
    Conditions
    Renal Failure
    Interventions
    elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-02-01
    Completion
    2020-03-05
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Failure
    Interventionelbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)
    PhasePhase 4
    Registry statusCompleted

  • Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C

    NCT03022006 · start 2017-01-15

    Registered record
    Registry ID
    NCT03022006
    Conditions
    Chronic Hepatitis C
    Interventions
    elbasvir, grazoprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-01-15
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    Interventionelbasvir, grazoprevir
    PhasePhase 4
    Registry statusUnknown

  • Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis

    NCT02973503 · start 2017-01-11

    Registered record
    Registry ID
    NCT02973503
    Conditions
    Chronic HCV Infection
    Interventions
    Elbasvir/Grazoprevir Fixed Dose Combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-01-11
    Completion
    2019-04
    Enrolment
    117

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic HCV Infection
    InterventionElbasvir/Grazoprevir Fixed Dose Combination
    PhasePhase 3
    Registry statusCompleted